Dr Rammohan Gumpeni, MD | |
5645 Main St, #wa 100, Flushing, NY 11355-5045 | |
(718) 670-1405 | |
(718) 461-2943 |
Full Name | Dr Rammohan Gumpeni |
---|---|
Gender | Male |
Speciality | Pulmonary Disease |
Experience | 56 Years |
Location | 5645 Main St, Flushing, New York |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1710069158 | NPI | - | NPPES |
061205476GU01 | Other | FAMILY HEALTH PLUS | |
124016 | Other | AETNA HMO | |
5C6148 | Other | HEALTHNET | |
11-3347168 | Other | MULTIPLAN | |
000000106306 | Other | GHI HMO | |
0C048P | Other | HIP | |
10209256 | Other | AMERIGROUP | |
4231839 | Other | AETNA PPO / POS | |
431637N | Other | CIGNA | |
DS486 | Other | OXFORD | |
000084001 | Other | AMERICHOICE | |
000197150101 | Other | HEALTHPLUS | |
11P6421 | Other | NYPRESBYTERIAN CHP | |
160039 | Other | ELDERPLAN | |
00200793 | Medicaid | NY | |
0074822 | Other | GHI PPO | |
100027142401 | Other | UNITED HEALTHCARE | |
693961 | Other | EMPIRE BC/BS |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207RP1001X | Internal Medicine - Pulmonary Disease | 111523 (New York) | Secondary |
207RP1001X | Internal Medicine - Pulmonary Disease | 111523-1 (New York) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
New York-presbyterian/queens | Flushing, NY | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
New York Queens Medicine And Surgery, P.c. | 4082883673 | 371 |
News Archive
In an ongoing effort to mirror the ability of biological tissues to respond rapidly and appropriately to changing environments, scientists from the McGowan Institute for Regenerative Medicine have synthesized a single, multifunctional polymer material that can decontaminate both biological and chemical toxins. They described the findings recently in Biomaterials.
Nutra Pharma Corp. (OTCBB: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that it has successfully completed a licensing agreement that grants XenaCare Holdings (OTCBB:XCHO) ongoing exclusive United States marketing and distribution rights for Cobroxin in return for meeting specific minimum performance requirements.
XOMA Ltd., a leader in the discovery and development of antibody therapeutics, announced results demonstrating that a murine equivalent of XOMA 052, its novel, high-affinity antibody to interleukin-1 beta (IL-1 beta), significantly reduced adverse consequences that usually lead to the development of congestive heart failure in a mouse model of acute myocardial infarction (heart attack).
John Ligerakis was told he had to learn to live with seizures that had made it challenging for him to work or drive a car. A young professional just starting his career, Ligerakis was devastated about what his future might bring.
› Verified 8 days ago
Entity Name | Newyork-presbyterian-queens |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1013960962 PECOS PAC ID: 7315839933 Enrollment ID: O20040329000273 |
News Archive
In an ongoing effort to mirror the ability of biological tissues to respond rapidly and appropriately to changing environments, scientists from the McGowan Institute for Regenerative Medicine have synthesized a single, multifunctional polymer material that can decontaminate both biological and chemical toxins. They described the findings recently in Biomaterials.
Nutra Pharma Corp. (OTCBB: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that it has successfully completed a licensing agreement that grants XenaCare Holdings (OTCBB:XCHO) ongoing exclusive United States marketing and distribution rights for Cobroxin in return for meeting specific minimum performance requirements.
XOMA Ltd., a leader in the discovery and development of antibody therapeutics, announced results demonstrating that a murine equivalent of XOMA 052, its novel, high-affinity antibody to interleukin-1 beta (IL-1 beta), significantly reduced adverse consequences that usually lead to the development of congestive heart failure in a mouse model of acute myocardial infarction (heart attack).
John Ligerakis was told he had to learn to live with seizures that had made it challenging for him to work or drive a car. A young professional just starting his career, Ligerakis was devastated about what his future might bring.
› Verified 8 days ago
Entity Name | New York Queens Medicine And Surgery, P.c. |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1003114851 PECOS PAC ID: 4082883673 Enrollment ID: O20110817000163 |
News Archive
In an ongoing effort to mirror the ability of biological tissues to respond rapidly and appropriately to changing environments, scientists from the McGowan Institute for Regenerative Medicine have synthesized a single, multifunctional polymer material that can decontaminate both biological and chemical toxins. They described the findings recently in Biomaterials.
Nutra Pharma Corp. (OTCBB: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that it has successfully completed a licensing agreement that grants XenaCare Holdings (OTCBB:XCHO) ongoing exclusive United States marketing and distribution rights for Cobroxin in return for meeting specific minimum performance requirements.
XOMA Ltd., a leader in the discovery and development of antibody therapeutics, announced results demonstrating that a murine equivalent of XOMA 052, its novel, high-affinity antibody to interleukin-1 beta (IL-1 beta), significantly reduced adverse consequences that usually lead to the development of congestive heart failure in a mouse model of acute myocardial infarction (heart attack).
John Ligerakis was told he had to learn to live with seizures that had made it challenging for him to work or drive a car. A young professional just starting his career, Ligerakis was devastated about what his future might bring.
› Verified 8 days ago
Mailing Address | Practice Location Address |
---|---|
Dr Rammohan Gumpeni, MD 7568 187th St, Fresh Meadows, NY 11366-1726 Ph: (718) 670-1405 | Dr Rammohan Gumpeni, MD 5645 Main St, #wa 100, Flushing, NY 11355-5045 Ph: (718) 670-1405 |
News Archive
In an ongoing effort to mirror the ability of biological tissues to respond rapidly and appropriately to changing environments, scientists from the McGowan Institute for Regenerative Medicine have synthesized a single, multifunctional polymer material that can decontaminate both biological and chemical toxins. They described the findings recently in Biomaterials.
Nutra Pharma Corp. (OTCBB: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that it has successfully completed a licensing agreement that grants XenaCare Holdings (OTCBB:XCHO) ongoing exclusive United States marketing and distribution rights for Cobroxin in return for meeting specific minimum performance requirements.
XOMA Ltd., a leader in the discovery and development of antibody therapeutics, announced results demonstrating that a murine equivalent of XOMA 052, its novel, high-affinity antibody to interleukin-1 beta (IL-1 beta), significantly reduced adverse consequences that usually lead to the development of congestive heart failure in a mouse model of acute myocardial infarction (heart attack).
John Ligerakis was told he had to learn to live with seizures that had made it challenging for him to work or drive a car. A young professional just starting his career, Ligerakis was devastated about what his future might bring.
› Verified 8 days ago
Ms. Min Cai, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 4105 College Point Blvd, Suite 1c, Flushing, NY 11355 Phone: 718-321-0558 Fax: 718-321-1672 | |
Dr. David Scott Rubin, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 13847 Horace Harding Expy, Flushing, NY 11367 Phone: 718-461-5813 Fax: 718-321-8095 | |
Xueshu Zhang, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 133-47 Sanford Avenue, Suite 1f, Flushing, NY 11355 Phone: 718-359-5780 Fax: 718-359-5821 | |
Haoxu Ouyang, Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 13227 41st Rd # 2c, Flushing, NY 11355 Phone: 718-269-5055 | |
Mu-i Karen Kuo, M.D. Pulmonary Disease Medicare: Medicare Enrolled Practice Location: 13259 41st Rd, Suite Cb, Flushing, NY 11355 Phone: 718-939-6234 Fax: 718-939-6235 | |
Evan Choi, M.D. Pulmonary Disease Medicare: Medicare Enrolled Practice Location: 5645 Main St, Flushing, NY 11355 Phone: 718-670-2000 | |
Dr. Mustafa Salehmohamed, D.O. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 5645 Main St, Wa-100, Flushing, NY 11355 Phone: 718-670-1405 |